Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Are We Considering All the Potential Drug–Drug Interactions in Women’s Reproductive Health? A Predictive Model Approach

ABSTRACT:

SUBMITTER: Garcia-Acero P

PROVIDER: S-EPMC12389331 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Similar Datasets

Women’s Reproductive Health Conditions and Fertility Goals

Project description: Not available

| S-EPMC12935700 | biostudies-literature

A new women’s health assay

Project description:A new sequencing-based women's health assay combining self-sampling, HPV detection and genotyping, STI detection, and vaginal microbiome analysis

| PRJEB25853 | ENA

An opinion evolution model for online social networks considering higher-order interactions.

Project description: Not available

| S-EPMC12002442 | biostudies-literature

Matrix Inequalities Based Robust Model Predictive Control for Vehicle Considering Model Uncertainties, External Disturbances, and Time-Varying Delay.

Project description: Not available

| S-EPMC7815701 | biostudies-literature

Associated factors of potential drug-drug interactions and drug-food interactions in patients with multiple sclerosis.

Project description: Not available

| S-EPMC9358348 | biostudies-literature

Women’s Cardiovascular Health and Cardiac Rehabilitation: a Priority-setting Partnership

Project description: Not available

| S-EPMC12946797 | biostudies-literature

DREAM, a Possible Answer to the Estrogen Paradox of the Women’s Health Initiative Trial

Project description:Estrogen is thought to cause proliferation of all estrogen receptor positive (ER+) breast cancers. Paradoxically, in the Women’s Health Initiative Trial, estrogen-only hormone replacement therapy reduced the incidence and mortality of low grade, ER+, HER2- breast cancer. We gave estradiol to 19 post-menopausal women with newly diagnosed low-grade, ER+, HER2- breast cancer in a prospective window of opportunity clinical trial and examined the changes in proliferation and gene expression before and after estradiol treatment. Ki67 decreased in 13/19 (68%) patients and 8/13 (62%) showed a decrease in Risk of Recurrence Score. We chose three prototypical estrogen responders (greatest decrease in ROR) and non-responders (no/minimal change in ROR) and applied a differential gene expression analysis to develop pre-treatment (PRESTO-30core) and post-treatment (PRESTO-45surg) gene expression profiles. The PRESTO-30core predicted adjuvant benefit in a published series of tamoxifen, the partial estrogen agonist. Of the 45 genes in the PRESTO-45surg, thirty contain the Cell cycle genes Homology Region (CHR) motif that binds the class B multi-vulva complex (MuvB) a member of the DREAM (Dimerization partner, retinoblastoma-like proteins, E2F, MuvB) complex responsible for reversible cell cycle arrest or quiescence. There was also near uniform suppression (89%) of the remaining DREAM genes consistent with estrogen induced activation of the DREAM complex to mediate cell cycle block after a short course of estrogens. To our knowledge, this is the first report to show hormonal modulation of DREAM genes and suggest involvement of DREAM pathway associated quiescence in endocrine responsive post-menopausal ER+ breast cancers.

2021-12-27 | GSE139688 | GEO

Dynamic Cloth Manipulation Considering Variable Stiffness and Material Change Using Deep Predictive Model With Parametric Bias

Project description: Not available

| S-EPMC9168129 | biostudies-literature

High-performance PBPK model for predicting CYP3A4 induction-mediated drug interactions: a refined and validated approach.

Project description: Not available

| S-EPMC11897275 | biostudies-literature

DEDTI versus IEDTI: efficient and predictive models of drug-target interactions.

Project description: Not available

| S-EPMC10247802 | biostudies-literature